Helping patients fight treatment resistant cancer.

resistanceBio can discover and overcome clinical treatment resistance

GET IN TOUCH
Life Line

A new paradigm in cancer treatment.

Cancer readily adapts to and resists treatment. Resistant cells become the prominent population in a tumor, creating an untreatable cancer. To prevent this outcome, resistanceBio has built a drug discovery pipeline capable of identifying a targeted multi-pronged attack that adapts to the tumor throughout treatment.

resistanceBio doesn’t see resistance mechanisms as cancer's superpower but instead as a definable and susceptible weakness. With our novel ResCu System, we mimic clinically reported cancer resistance mechanisms, generating a proprietary biobank of resistant cancer cell populations. Leveraging multi-omics measurements, we define the cause of resistance and identify novel biomarkers, drug targets, and drug candidates. Screening these drugs against the biobank, resistanceBio generates a new therapy class—Resistance Therapy—that can attack a complex intractable tumor and drive it to a simpler, more susceptible state.

cancer-treatment NewTreatment Mobile New
resistanceBio:

Opportunities for Biopharma

Resistancs

Resistance Profile Program

Streamlined Project to understand how cancer responds to a therapy over time

Biomarker

Biomarker Discovery for Companion Diagnostics

Identify biomarkers of treatment success and resistance

Therapeutic

Therapeutic Discovery and Co-Development

Discover novel multi-targeted therapeutic approaches that overcome treatment resistance

Gray Line

Better treatments are discovered by understanding and overcoming resistance

GET IN TOUCH
Man
Therapy

Tumors are complex and often already resistant to many treatments

Cancer is dynamic and diverse allowing it to quickly adapt to therapy. Effective strategies require a multi-targeted approach.

Rescu

We built the ResCu System to model cancer resistance in dynamic cell populations

Small populations of cancer cells in a tumor affect the larger disease progression.

Medicine

The result?
Resistance Therapy.

Multi-targeted cancer therapy that takes into account the current and future state of the tumor steering it towards a susceptible state.

TreatmentBg

Discover the research behind the science

Team BgTeam Mobile
Gray Line

Meet the Team at resistanceBio  

Powered by diverse experience, driven by the same life-saving mission

Nick Golder, PhD
CEO and Co-Founder
Chris Bulow, PhD
COO and Co-Founder
Lindsay Hill, PhD
Platform Engineer II
Jonathan Zhu
Research Associate - Cancer Organoids
Manasa Gadde, PhD
Organoid Scientist
Michael Williams
Head of Business Development
Nick Golder, PhD
CEO and Co-Founder
Nick Golder, PhD
CEO and Co-Founder
Nick Golder, PhD
CEO and Co-Founder
Chris Bulow, PhD
COO and Co-Founder
Michael Williams
Head of Business Development
Lindsay Hill, PhD
Platform Engineer II
Jonathan Zhu
Research Associate - Cancer Organoids
Manasa Gadde, PhD
Organoid Scientist

Meet the Advisory Board

Jacob Scott, MD,DPhil
Clinical Assistant Professor, Cleveland Clinic
Nathan Pennell, MD, PHD
Vice Chair of Clinical Research and Director, Lung Cancer Medical Oncology Program, Cleveland Clinic
Michalina Janiszewska, PHD
Assistant Professor at The Scripps Research Institute
Christina Curtis, PhD
Associate Professor of Medicine and Genetics Stanford University School of Medicine, Co-Director, Molecular Tumor Board, Stanford Cancer Institute
Elana Fertig, PhD
Assistant Director of Research Program in Quantitative Sciences, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Michael Kattan, PhD
The Dr. Keyhan and Dr. Jafar Mobasseri Endowed Chair for Innovations in Cancer Research, Quantitative Health Sciences, Cleveland Clinic
Jacob Scott, MD,DPhil
Clinical Assistant Professor, Cleveland Clinic
Jacob Scott, MD,DPhil
This is some text inside of a div block.
Jacob Scott, MD,DPhil
Clinical Assistant Professor, Cleveland Clinic
Nathan Pennell, MD, PHD
Vice Chair of Clinical Research and Director, Lung Cancer Medical Oncology Program, Cleveland Clinic
Michalina Janiszewska, PHD
Assistant Professor at The Scripps Research Institute
Christina Curtis, PhD
Associate Professor of Medicine and Genetics Stanford University School of Medicine, Co-Director, Molecular Tumor Board, Stanford Cancer Institute
Elana Fertig, PhD
Assistant Director of Research Program in Quantitative Sciences, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Michael Kattan, PhD
The Dr. Keyhan and Dr. Jafar Mobasseri Endowed Chair for Innovations in Cancer Research, Quantitative Health Sciences, Cleveland Clinic
Life Line
Life Line
Gray Line
Life Line

We’re breathing new life into the fight against cancer. Join us.

GET IN TOUCH
Needspurchasing
cancer-institute
YC
Dreamers-vc
Cherubiclogo
l2-ventures
Svangel